Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial
Roser Pinyol, Robert Montal, T. Takayama, Gar‐Yang Chau, Vincenzo Mazzaferro, S. Roayaie, H.C. Lee, Rtp Poon, N. Kokudo, Z. Zhang, Laia Bassaganyas, Sara Torrecilla, Agrin Moeini, Leonardo Rodríguez‐Carunchio, Edward Gane, Chris Verslype, Adina Croitoru, Umberto Cillo, Manuel de la Mata, L. Lupo, Simone I. Strasser, J.-W. Park, Jordi Camps, María A. Solé, S N Thung, A. Villanueva, Carol E. Peña, G. Meinhart, Jordi Bruix, Josep M. Llovet (2017). Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial. Journal of Hepatology, 66(1), pp. S12-S13, DOI: 10.1016/s0168-8278(17)30287-8.
